alendronate has been researched along with Dermatitis Medicamentosa in 4 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrantes-González, M | 1 |
| Espona-Quer, M | 1 |
| Salas, E | 1 |
| Giménez-Arnau, AM | 1 |
| Kimura, M | 1 |
| Kawada, A | 1 |
| Murayama, Y | 1 |
| Murayama, M | 1 |
| Brinkmeier, T | 1 |
| Kügler, K | 1 |
| Lepoittevin, JP | 1 |
| Frosch, PJ | 1 |
| García Ortega, P | 1 |
| Carrascal Martín, M | 1 |
| Herrero Baladrón, M | 1 |
| Pérez Martín, R | 1 |
4 other studies available for alendronate and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Bisphosphonate-induced cutaneous adverse events: the difficulty of assessing imputability through patch testing.
Topics: Aged; Alendronate; Case-Control Studies; Diphosphonates; Drug Eruptions; Female; Humans; Ibandronic | 2014 |
Drug eruption due to alendronate sodium hydrate.
Topics: Aged; Alendronate; Drug Eruptions; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; | 2003 |
Adverse cutaneous drug reaction to alendronate.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Drug E | 2007 |
[Toxicoderma associated with alendronate].
Topics: Aged; Alendronate; Drug Eruptions; Female; Humans | 2002 |